New study aims to unravel mysteries of immune disorder complications
NCT ID NCT07526714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of about 60 people with primary immune deficiencies who also developed lymphoproliferative disorders (abnormal growth of immune cells). The goal is to track their health over time, including risks of death, cancer, or organ damage. By identifying patterns and risk factors, researchers hope to improve monitoring and care for this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult and pediatric patients diagnosed with a primary immunodeficiency (PID) who exhibit lymphoproliferation, with or without associated autoimmune manifestations. Patients are followed longitudinally to assess clinical outcomes, comorbidities, treatment responses, and correlation with cellular phenotypes. Exclusion criteria include secondary immunodeficiencies, active malignancies unrelated to PID, or inability to provide informed consent.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of primary immunodeficiency (inborn error of immunity) according to ESID criteria * Presence of systemic lymphoproliferative manifestations (e.g., persistent lymphadenopathy, splenomegaly, lymphoma) and/or organ involvement attributable to lymphocytic or granulomatous infiltration * Diagnosis of lymphoproliferative manifestation between January 1, 2014 and December 31, 2025 * Minimum follow-up of 12 months after diagnosis of lymphoproliferative manifestation * Followed in one of the participating centers Exclusion Criteria: * Secondary immunodeficiency (e.g., HIV infection, immunosuppression due to chemotherapy, solid organ transplantation, or other acquired causes) * Isolated reactive lymphadenopathy clearly attributable to acute infection without evidence of persistent lymphoproliferation * Insufficient clinical data available in medical records to assess baseline characteristics or outcomes * Follow-up duration \< 12 months after diagnosis of lymphoproliferative manifestation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Benign lymphoproliferative disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.